HCRN GU20-444
Neoadjuvant Pembrolizumab for Muscle-Invasive Bladder Cancer with Selective Bladder Sparing
Learn more:
- clinicaltrials.gov: #NCT05406713
Neoadjuvant Pembrolizumab for Muscle-Invasive Bladder Cancer with Selective Bladder Sparing
Learn more:
Facebook
Hoosier Cancer Research Network on Facebook
Linked In
You Tube
Twitter